Mankind Pharma Introduces Dydroboon 30mg Sustained Release Tablets for Treatment of Endometriosis
Written By : Dr. Nandita Mohan
Written By : MD Brand Connect
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-03-05 06:16 GMT | Update On 2024-08-17 05:55 GMT
Advertisement
Opening doors to convenience for patients suffering from endometriosis, Mankind Pharma, a leading Indian pharmaceutical company, has announced the launch of Dydroboon 30mg Sustained Release tablets in India.
Dydroboon 30mg is approved by DCGI for the treatment of endometriosis. It contains Dydrogesterone 30 mg in the sustained-release tablet dosage form.
Women suffering from endometriosis have to consume 2-3 pills of Dydrogesterone daily, increasing their pill burden. Dydroboon 30mg sustained release tablets ensure drug release for a longer time, mitigating this practical burden of treatment inconvenience. It increases the chances of treatment adherence and helps the patient with the convenience of once daily dose of the drug.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.